MC Services is an international Corporate Communications and Investor Relations firm providing Life Sciences companies high-level consultancy, targeted services and support throughout Europe and beyond
Our Services
Corporate Communications
Designing, implementing and effectively operating international Corporate Communications programs is part of our core expertise.
Investor Relations
Our trained senior Investor Relations specialists provide a unique opportunity to have immediate access to the necessary tools, skills and networks you need in Europe, the UK and the US.
Roadshows & Transactions
Product & Science PR
Right from its scientific beginnings, and all the way through regulatory approval and market launch we support the strategic positioning and marketing of your product – and the science behind it – to the relevant stakeholders.
SELECTED CLIENTS – PAST AND PRESENT
Client News
Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod
InflaRx to Report Second Quarter 2026 Results on August 6, 2026
Promatix Biosciences Awarded Innovate UK Biomedical Catalyst Grant to Advance First-in-Class EGFR × EphA2 Cis-Bispecific ADC
MC Services is Supporting Partner for LSX World Congress USA
We are proud to support again this year LSX World Congress USA, taking place on September 23-24, 2026 in Boston, MA, as part of Biotech Week Boston.
Built around the theme “Powering Biotech Growth Through Capital and Pharma Partnerships,” the event gathers 1000+ leaders from the US biotech, medtech, and pharmatech sectors to network, showcase innovations, and explore partnership and scout high-growth opportunities.
MC Services is media partner for BIO-Europe 2026
MC Services is proud to once again support BIO-Europe as official media partner. Taking place from November 9–11, 2026, in Cologne, Germany, BIO-Europe is the global strategic biopharma platform where senior industry leaders connect, align on priorities, and advance partnerships.
The 2026 edition will bring together more than 5,800 participants from over 3,200 companies across more than 60 countries, including biotech and pharma executives, investors and strategic partners. While partnering remains central, the program will also address broader industry priorities, from investment and dealmaking to clinical, regulatory and manufacturing strategy.
For more information on the program, timing and additional activities, please visit the event’s website.